Investigating how copper metabolism can be targeted to develop new cancer therapies
Targeting vulnerabilities in copper metabolism in the development of cancer therapies
This study is looking at how copper affects cancer growth and is testing a new way to slow down tumors by using special substances that limit copper for cancer cells, which could lead to better treatments for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10897180 on NIH RePORTER |
What this research studies
This research focuses on the role of copper in cancer cell growth and how it can be manipulated to create new treatments. It explores the use of copper chelators, which are substances that bind copper and reduce its availability to cancer cells, potentially slowing tumor growth and metastasis. The study aims to specifically target a copper transporter called ATP7A, which is crucial for delivering copper to enzymes that promote cancer progression. By understanding and targeting these pathways, the research seeks to develop more effective cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer or other cancers that have shown sensitivity to copper depletion therapies.
Not a fit: Patients with cancers that do not rely on copper metabolism for growth may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that slow down cancer progression and improve survival rates for patients.
How similar studies have performed: Previous studies have shown promising results with copper depletion strategies in cancer treatment, indicating that this approach has potential based on earlier successes.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Petris, Michael J. — University of Missouri-Columbia
- Study coordinator: Petris, Michael J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.